Tobramycin Inj Rx
Generic Name and Formulations:
Tobramycin sulfate 10mg/mL, 40mg/mL; soln for IM inj or IV infusion after dilution; contains 1.56mg sodium per 20mg/mL vial; contains sulfites.
Various generic manufacturers
Indications for Tobramycin Inj:
Serious susceptible infections, including lower respiratory tract, CNS (eg, meningitis), intraabdominal (eg, peritonitis), septicemia, bone, skin and skin structure, complicated and recurrent UTIs or uncomplicated UTIs not susceptible to other antibiotics.
Obesity: base dose on lean body mass. Give by IM inj; or IV infusion over 20–60 mins. Serious infections: 3mg/kg/day in 3 divided doses every 8 hours. Life-threatening infections: up to 5mg/kg/day in 3–4 divided doses; max 5mg/kg/day unless serum levels monitored; reduce to 3mg/kg/day as soon as clinically indicated. Usual duration: 7–10 days. Severe cystic fibrosis: initially 10mg/kg/day in 4 divided doses; adjust dose based on serum levels. Renal impairment: reduce dose; see literature.
Give by IM inj; or IV infusion over 20–60 mins. Premature or neonates ≤1 week: up to 4mg/kg/day in 2 divided doses every 12 hours. All others >1 week: 6–7.5mg/kg/day in 3–4 divided doses (2–2.5mg/kg every 8 hours or 1.5–1.89mg/kg every 6 hours). Usual duration: 7–10 days. Renal impairment: reduce dose; see literature.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >12micrograms/mL and trough levels >2micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Do audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D): not recommended.
Avoid concomitant furosemide, ethacrynic acid, other nephro/neurotoxic drugs including cephalosporins. Diuretics may increase toxicity. May potentiate neuromuscular blocking agents.
Nephro- or neurotoxicity, lethargy, confusion, headache, inj site reactions, GI upset, elevated liver enzymes, blood dyscrasias, electrolyte abnormalities, respiratory failure or paralysis, neuromuscular blockade; rare: serious allergic reactions (eg, anaphylaxis, exfoliative dermatitis, Stevens-Johnson Syndrome).
Formerly known under the brand name Nebcin.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases